Holi, a Polish HealthTech startup building a digital obesity clinic, has raised €3 million in Seed funding to enter new European markets and further develop its data-driven care platform.
The round led by 4growth VC (Poland) with participation from YZR Capital (Germany), Heartfelt Capital (Germany) and a group of business angels.
“Obesity treatment requires continuity and the integration of multiple medical competencies,” says Paweł Seweryn, Founder & CEO of Holi. “Our goal is to deliver a comprehensive solution that leads to real, long-term change in metabolic health. The funding will enable us to scale our model internationally – starting with the Southern and Eastern Europe markets, which are highly receptive to private healthcare and telemedicine – while further developing our technology stack.”
Holi’s Seed round situates the company within a visibly active 2025 European HealthTech and digital obesity-care landscape. Several peers have also attracted capital this year:
Numan (UK, London) raised €51.6 million to expand its preventative digital-health platform, which includes obesity and hormonal health management.
Doctor.One (Poland, Warsaw) secured €4 million to grow its asynchronous chronic-care model – covering obesity among other conditions – into Western European markets.
Ciloa (France, Montpellier) obtained €6.5 million to progress exosome-based therapies targeting metabolic diseases such as obesity and type 2 diabetes.
Together, these examples illustrate increasing investor attention to obesity treatment and metabolic-care innovation. The fact that another Polish startup, Doctor.One, raised funds in the same year highlights Poland’s growing presence in European digital healthcare.
EU-Startups previously covered Holi’s €680k pre-Seed round in 2023, underscoring its early traction in the region. Within this context, Holi’s new funding reflects a steady progression from proof-of-concept toward regional scale-up – aligned with broader 2025 trends in hybrid, data-driven models for metabolic health management.
“The next generation of obesity treatment will be hybrid – data and AI for precision, experts for impact. Our platform continuously analyses patient data to adjust therapy in real time, while doctors and specialists step in exactly when human intervention matters most. That’s how we deliver better outcomes with smarter use of medication,” explains Jan Kundziołka, Co-founder of Holi, responsible for product and technology.
Founded in 2023, Holi is a digital obesity clinic that combines multidisciplinary medical care (doctors, psychodietitians, psychologists, physiotherapists) with technology that supports lifestyle change and pharmacotherapy.
It also provides access to GLP-1-based pharmacotherapy, including drugs such as Ozempic and Wegovy.
Through its mobile app and specialist platform, Holi aims to deliver personalised treatment plans and continuous patient monitoring. It operates on a subscription-based model and focuses on improving metabolic health by treating the root causes – not just the symptoms – of obesity.
The funds will be allocated to scaling Holi’s medical infrastructure and enhancing its technology capabilities, including diagnostics integration, GLP-1 tracking, automation of care processes and new engagement features designed to sustain patient motivation over time.
According to data provided by the company, patients using the platform achieve on average a 17% reduction in body weight after 12 months – around 1.5x more than pharmacotherapy alone. By combining data-driven dose optimisation with behavioural coaching, Holi reprotedly helps patients cut their medication costs by up to 50%.
According to WHO data, more than 800 million people worldwide are currently living with obesity, and nearly two billion are overweight. Obesity is now classified as one of the largest global public health challenges, contributing to more than 200 medical conditions and driving increasing pressure on healthcare systems.
“Obesity remains one of the most underserved health needs globally. Holi has built a truly efficient care model – virtual, scalable and designed with a genuine value-for-money mindset. It delivers clinically proven outcomes at a price point that makes sense for both patients and the business. This combination of medical impact and smart product design is exactly what convinced us to invest,” says Krzysztof Bachta, Managing Partner at 4growth VC.
The EU obesity treatment market is estimated at €40-50 billion, with private healthcare spending rising rapidly as GLP-1 drugs such as Ozempic, Wegovy and Mounjaro become more widely adopted by patients.
“Since our initial investment, Holi has shown remarkable progress – both in clinical outcomes and operational execution. The company is scaling fast while maintaining strong medical standards, which is rare in this market. That’s exactly why we decided to significantly increase our backing in this round,” says Markus Feuerecker, Co-founder and Managing Partner at YZR Capital.
Read the orginal article: https://www.eu-startups.com/2025/11/with-800-million-people-living-with-obesity-worldwide-warsaws-holi-secures-e3-million-to-expand-its-digital-treatment-platform/
